Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Cash from Financing Activities: 2010-2021

Historic Cash from Financing Activities for Neurocrine Biosciences (NBIX) over the last 11 years, with Dec 2021 value amounting to $1.8 million.

  • Neurocrine Biosciences' Cash from Financing Activities rose 100.97% to $1.8 million in Q4 2021 from the same period last year, while for Dec 2021 it was $27.4 million, marking a year-over-year increase of 117.36%. This contributed to the annual value of -$486.7 million for FY2024, which is 845.33% down from last year.
  • Per Neurocrine Biosciences' latest filing, its Cash from Financing Activities stood at $1.8 million for Q4 2021, which was down 76.00% from $7.5 million recorded in Q3 2021.
  • Neurocrine Biosciences' 5-year Cash from Financing Activities high stood at $506.5 million for Q2 2017, and its period low was -$185.0 million during Q4 2020.
  • In the last 3 years, Neurocrine Biosciences' Cash from Financing Activities had a median value of $5.7 million in 2020 and averaged -$8.2 million.
  • As far as peak fluctuations go, Neurocrine Biosciences' Cash from Financing Activities skyrocketed by 54,012.50% in 2017, and later slumped by 1,591.94% in 2020.
  • Quarterly analysis of 5 years shows Neurocrine Biosciences' Cash from Financing Activities stood at $5.6 million in 2017, then slumped by 68.71% to $1.8 million in 2018, then spiked by 607.76% to $12.4 million in 2019, then plummeted by 1,591.94% to -$185.0 million in 2020, then surged by 100.97% to $1.8 million in 2021.
  • Its Cash from Financing Activities was $1.8 million in Q4 2021, compared to $7.5 million in Q3 2021 and $3.0 million in Q2 2021.